Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 3Gastro-enteropancreatic neuroendocrine tumor 3Adenoma, Islet Cell 2Recurrence 1Pancreatitis 1Pancreatic Intraductal Neoplasms 1Meningioma 1Fistula 1Duodenal Neoplasms 1Carcinoid Tumor 1Acromegaly 1

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Temozolomide 3sargramostim 2montanide ISA 51 2lutetium Lu 177 dotatate 2incomplete Freund's adjuvant 2Sunitinib 2Octreotide 2Everolimus 2Colony-Stimulating Factors 2Capecitabine 2sapanisertib 1lanreotide 1fludarabine phosphate 1cabozantinib 1belzutifan 1atezolizumab 1aflibercept 1abemaciclib 1X-Rays 1Salts 1Phantoms, Imaging 1PM 01183 1Methods 1LY2940680 1Interleukin-13 1Injections 1Immunoglobulin G 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × Octreotide × 1 year × Clear all
NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03879694 2026-02-06

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Roswell Park Cancer Institute

Phase 1 Completed
19 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡